RADAR-PGx Registry defining Adverse Drug (ADR) improvement measures with medication optimization for effectiveness and safety.
Pharmacogenomic Testing for Medication Management

The way individuals metabolize medicine is often influenced by their genes. There is a known genetic variance from one individual to another. The study of the role genetics plays in the body's ability to process medicine is called pharmacogenomics.

We are enrolling healthcare providers to assist in gathering data for pharmacogenomic testing (PGx) to help manage patient medication regimens and assess if testing can have a positive impact in avoiding adverse drug events, hospitalization and emergency department visits. Moreover, can PGx testing help physicians meet medication adherence incentive measures for certain drug classes such as statins, RAS Antagonist and oral diabetes.

Primary Objective

To evaluate the value of PGx in managing patients who are taking drugs with metabolic pathways known to be influenced by genetic variation.

Secondary Objective

To determine if the frequency of adverse drug events is reduced with PGx testing, and evaluate the effect of PGx testing on the requirements for emergency department visits and hospitalizations for drug-related adverse events.

Eligible Drug Classes

Analgesics
Anti-infectives
Antidepressants
Anticonvulsants
Antihypertensives
Barbiturates
Clopidogrel
Diuretics
Muscle relaxers
Opioids
SSRIs
Steroids
Antiallergenics
Antiarrythmics
Anticoagulants
Anitepileptics
Antipsychotics
Benzodiazepines
CNS stimulants
Methadone
NSAIDs
Proton inhibitors
Statins
Vasodilators

Honorarium

An honorarium is available to healthcare provider upon completion of the trial survey for patients enrolled in the study.

Inclusion Criteria

- Patient underwent PGx testing for alleles appropriate to the target drugs within the prior 120 days ("index PGx test");
- Patient was receiving at least one medication known to be associated with allelic variation at the time of the index PGx test, including over-the-counter medications;
- Patient has a history of at least one Target Drug Adverse Event (TDAE) over the 24 month period preceding receipt of PGx test results, or has experienced inadequate efficacy from a target drug;
- Patient is able and willing to provide written informed consent;
- Patient is a male or female over 25 years of age.

Exclusion Criteria

Patients will be excluded if any of the following criteria apply:

- Patient is currently hospitalized;
- Patient's medical and medication history is unavailable over the 120-day period preceding the receipt of PGx test results;
- Patient is unable to provide an accurate history due to mental incapacity;
- Subject is known to have undergone prior PGx testing for genes specific to the target drug(s), exclusive of the PGx test relating to this Registry.

Genomic Assessments

The Registry will assess genes associated with a patient's target medications or with substitute medications considered as replacements for target drugs.

Additional genes and variants may be included in the protocol as the body of knowledge of PGx testing expands.

This is intended as a general overview of the protocol and benefits. If you have questions pertaining to the clinical study please email TheRadarStudy@radar-pgxstudy.com.

www.clinicaltrials.gov / NCT #02738047